Beijing Winsunny Pharmaceutical Co Ltd
SSE:601089
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
B
|
Beijing Winsunny Pharmaceutical Co Ltd
SSE:601089
|
5.2B CNY |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
978.7B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.3B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
277.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
210B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
220.8B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
273B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.6T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
150.2B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
95.7B EUR |
Loading...
|
Market Distribution
| Min | -409 046.1% |
| 30th Percentile | -1.4% |
| Median | 4.2% |
| 70th Percentile | 10.3% |
| Max | 876.4% |
Other Profitability Ratios
Beijing Winsunny Pharmaceutical Co Ltd
Glance View
In the bustling epicenter of China's pharmaceutical landscape lies Beijing Winsunny Pharmaceutical Co Ltd, a dynamic player that expertly navigates the intricacies of modern healthcare needs. Established as a frontrunner in the production of both active pharmaceutical ingredients (APIs) and finished dosage forms, Winsunny has carved out a niche by marrying traditional pharmaceutical craftsmanship with innovative technological advancements. The company focuses predominantly on the cardiovascular and gastrointestinal therapeutic segments, diligently working to bring cutting-edge treatments to global markets. Leveraging state-of-the-art research and development facilities, Winsunny fosters a culture of continuous innovation and stringent quality assurance, ensuring its offerings not only meet but often exceed regulatory requirements. This emphasis on quality and innovation anchors its reputation as a reliable partner in the pharmaceutical supply chain, both within China and internationally. Winsunny's financial health and traction in the market are built upon a versatile business model that capitalizes on both proprietary research and strategic partnerships. By investing heavily in R&D, the company pioneers new drugs while simultaneously improving existing formulations to enhance efficacy and safety profiles. Furthermore, Winsunny’s strategic alliances with global pharmaceutical giants enable it to expand its market reach and distribution networks. This synergistic approach, coupled with a keen eye on operational efficiencies, allows Winsunny to maintain competitive pricing without compromising on quality. As healthcare demands continue to evolve, the company stands agile, ready to adapt and address these shifts, ensuring its place as a stalwart in the pharmaceutical industry and a significant contributor to global health advancements.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Beijing Winsunny Pharmaceutical Co Ltd is 14.6%, which is above its 3-year median of 14.5%.
Over the last 3 years, Beijing Winsunny Pharmaceutical Co Ltd’s Operating Margin has increased from 13.1% to 14.6%. During this period, it reached a low of 13% on Sep 30, 2022 and a high of 15.3% on Jun 30, 2024.